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Abstract
Introduction and objective. Lymph node involvement is a strong predictor of disease recurrence and patient survival in 
vulvar cancer. The aim of the study was to evaluate the feasibility of sentinel lymph node (SLN) screening, the incidence of 
skip metastases, and lymph node lymphangiogenesis.  
Materials and method. Fifty-five patients participated in this prospective, single centre study. A double SLN screening 
method was employed using radiocolloid (technetium-99 sulfur colloid) and 1.0% Isosulfan Blue. Immunohistochemistry, 
using a mouse monoclonal antibody against D2–40, was used to evaluate lymphatic vessel density (LVD). All calculations 
were performed using STATISTICA software v. 10 (StatSoft, USA, 2011); p < 0.05 was considered significant.  
Results. Using both methods of SLN detection, 100% accuracy was achieved, and skip metastases were diagnosed in only 
one woman (1.82%). Peri-tumour median LVD was significantly increased compared with matched intra-tumour samples 
(p < 0.001), while median LVD was significantly lower in negative, compared with positive SLN, regardless of whether matched 
non-SLN were negative (p < 0.001) or positive (p = 0.005). Metastatic SLN exhibited significantly higher median LVD compared 
with matched negative non-SLN (p = 0.015), while no significant difference in median LVD was detected between positive 
SLN and matched positive non-SLN. However, negative SLN had a significantly higher median LVD compared with matched 
negative non-SLN (p = 0.012).  
Conclusions. SLN detection is a safe and feasible procedure in vulvar cancer. In patients without nodular involvement, SLN, 
compared with non-SLN, exhibited significantly higher median LVD, which may be an indication of its preparation to host 
metastases, and thus requires further investigation.
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INTRODUCTION
Vulvar carcinomas, among which the squamous type is 
most frequent, are rare gynaecological malignancies mainly 
affecting elderly women [1, 2]. Vulvar cancers predominantly 
metastasize via the lymphatic system, with the inguinofemoral 
lymph nodes a major site of metastases, and the extent of 
lymph node involvement is a strong predictor of disease 
recurrence and patient survival [3].
Regional lymph node metastases usually occur via the 
sentinel lymph node (SLN), which is the first draining lymph 
node to which the primary tumor is likely to spread [4]. 
The concept of sentinel node biopsy in vulvar cancer has 
been broadly studied and a consensus on its clinical value 
established, which maintains that women with unifocal 
primary vulvar cancer and tumour size < 4  cm, without 
clinical evidence of inguinofemoral lymph node involvement, 
will benefit greatly from SLN sampling [4].
Historically, lymphatic vessels were considered passive 
participants in tumour metastasis, simply providing channels 
for tumour cells to transit to draining lymph nodes, and 
lymph nodes were likened to sieves, trapping cancer cells 
[5]. Currently, it is generally accepted that tumour-associated 
lymphatic vessels have active roles in cancer development, 
while lymph nodes are assumed to be a reservoir for tumour 
cells, from which they can take root and form metastatic 
tumours [6]. Tumour-induced lymphangiogenesis is believed 
to promote cancer metastasis to lymph nodes, although 
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reported data are not equally robust for all types of tumours, 
and some contradictory results have been published [6]. 
The results of studies using animal models suggest that 
tumour-associated lymphangiogenesis has potential 
significance, not only at the primary site, but also in lymph 
nodes. Hence, it is likely that primary tumours can induce 
new lymphatic vessel growth in draining lymph nodes 
before metastasis [5, 7]. SLN lymphangiogenesis has been 
identified in cutaneous malignant melanoma, breast cancer, 
and extramammary Paget’s disease; however, compared 
with tumour lymphangiogenesis, the role of lymph node 
lymphangiogenesis remains largely unexplored [6, 8, 9].
The current study included women with unifocal 
squamous vulvar cancer and was designed to: (1) validate 
the feasibility of the SLN procedure for these patients, (2) 
estimate the incidence of skip metastases, and (3) evaluate 
the intensity of tumour and lymph node lymphangiogenesis 
in primary vulvar cancer, and determine the correlation 
between this process and tumour and lymph nodes using 
immunohistochemistry.
MATERIALS AND METHOD
This single centre prospective study was performed between 
2010–2016 in the Department of Gynaecology and Oncology 
of the Jagiellonian University in Krakow, Poland, and was 
approved by the Jagiellonian University Ethics Board. Women 
with primary unifocal squamous vulvar cancer with tumours 
< 4 cm, localized > 2 cm laterally from the median line, and 
with no evidence of inguinofemoral lymph node involvement, 
were considered eligible for the study. Patients with: (1) non-
squamous type vulvar cancer, (2) clinically or image positive 
inguinofemoral lymph nodes, (3) vulvar cancer recurrence, 
(4) history of vulvar/pelvic/abdominal radiation therapy, and 
(5) incomplete data, were excluded. After taking a history 
from each patient initially diagnosed with squamous vulvar 
cancer based on histopathological analysis of a vulvar biopsy, 
the patients were examined gynaecologically and rectally, 
the results reviewed, and additional laboratory and imaging 
tests performed. Subsequently, the patients considered by a 
gynecology/oncology consultant to be eligible for primary 
surgical treatment were included.
Surgical treatment and sentinel lymph node (SLN) detection 
procedure. Based on primary tumour diameter and 
localization, radical local excision or radical vulvectomy was 
performed, followed by unilateral systemic inguinofemoral 
lymphadenectomy. Patients with primary tumours localized 
≤ 2 cm from the median line were excluded from the study. 
Prior to lymphadenectomy, SLN biopsies were performed 
in every patient by a high-volume radical vulvectomy 
surgeon, according to the trial protocol. For SLN detection, 
radiocolloid (Technetium-99 sulfur colloid) was injected 
intradermally 180 (± 10) min prior to surgery, using a four-
point injecting technique at 2, 5, 7, and 10 ò clock peri-
tumourally. A gamma-probe was used for SLN identification 
before an inguinal incision was made to localize the optimal 
surgical approach. Isosulfan Blue (1.0%, 1 cm3) (Patent Blue V, 
Guerbert GmbH, Sulzbach, Germany) was also injected peri-
tumourally using the same four-point injecting technique 20 
(± 5) min before surgery. The SLN procedure was performed 
prior to vulvectomy.
Histopathological evaluation and detection of lymphatic 
vessels. Postsurgical histopathological staging using 
FIGO 2009 classification and grading was performed 
on haematoxylin and eosin-stained slides, according to 
standard histopathological procedures, which confirmed 
the presence of squamous vulvar cancer in each patient 
[10]. Immunohistochemistry (IHC) of the lymphatic vessels 
detection was performed using a mouse monoclonal antibody 
against D2–40 (Anti-D240 antibody [D2–40]; Abcam, 
Cambridge, MA, USA), a new selective marker of lymphatic 
endothelium. IHC was performed on 4–5 μm thick tissue 
sections. Slides were deparaffinized and dehydrated in 100% 
ethanol, washed in distilled water, and microwaved (600 W 
for 10 min and 5 min) in antigen retrieval solution (EDTA, 
pH 8.0). Next, they were washed in distilled water, cooled 
at room temperature (RT) for 20–30 min, and immersed in 
3% H2O2 to block endogenous peroxidase. After washing 
in distilled water (5 min) and Wash Buffer (Tris-HCl; 
DakoCytomation, S3006; Agilent Technologies LDA, Ltd., 
Stockport, Cheshire, UK) twice for 5 min, 100 µl of gamma-
glutamyltransferase 1 precursor antibody (GGT1; polyclonal 
(Thermo Scientific PA5–21344; Agiliens Technologies 
LDA, Ltd., Stockport, Cheshire, UK), diluted 1:400 in Dako 
Antibody Diluent with Background Reducing Components 
(Agiliens Technologies LDA, Ltd., Stockport,Cheshire, UK), 
was applied to each tissue section. Next, slides were incubated 
for 30 min at RT. After washing in Wash Buffer, secondary 
antibody (Dako Real EnVision HRP Rabbit/Mouse, K5007; 
Agiliens Technologies LDA, Ltd., Stockport, Cheshire, UK) 
was applied and incubated for 30 min at RT. peri-tumoural 
borders Visualization was performed using DAB (10–30 sec).
Lymphatic vessel density (LVD) using D2–40 staining, 
was evaluated in each tumour specimen, and in SLNs and 
non-SLNs, in 10 high-power fields (hpf; magnification x400), 
and expressed as the median number of lymphatic vessels 
per 1 mm2. In cases where more than one SLN was identified, 
the median LVD of all nodes was calculated and used for 
the analysis. Similarly, median LVD for non-SLNs was 
calculated and analyzed. Each sample was assessed blindly 
by two independent observers. In the case of any discrepancy 
between the observations, samples were examined again, 
together, to achieve a consensus.
Statistical analysis. The Shapiro-Wilk test confirmed that 
analyzed variables were non-normally distributed. Data 
are presented as medians and interquartile range (IQR) or 
number of cases and percentage. Mann-Whitney U analysis 
was chosen for comparisons of independent groups of 
patients, while the Wilcoxon pair test was used to analyze 
LVD in consecutive lymph node samples. The Kruskal-
Wallis one-way analysis of variance with post-hoc testing 
when appropriate, was chosen to evaluate comparisons of 
more than two groups of variables. A univariate regression 
model was used to evaluate the relationship of LVD with 
clinicopathological characteristics. p = 0.05 was accepted 
as statistically significant. All calculations were performed 
using STATISTICA software v. 10 (StatSoft. 2011, Tulusa, 
OK, USA).
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RESULTS
Clinical characteristics. From a group of 72 participants who 
were prospectively enrolled into the study, 55 finally met 
the inclusion criteria (Fig. 1). Fourteen patients (25.45%) 
underwent unilateral radical vulvectomy and 41 (74.55%) 
underwent radical local tumour excision, followed in each case 
by unilateral systemic inguinofemoral lymphadenectomy. 
The median age of the included women was 72 years (IQR: 
7.5 years). Detailed clinicopathological characteristics of 
patients are presented in Table 1.
Feasibility of the SLN procedure and risk of skip metastases. 
The SLN identification procedure using Isosulfan Blue 
failed in four women (7.27%) and in one woman (1.82%) 
using radiocolloid, indicating the high level of accuracy of 
each dye separately (92.73% and 98.18%, respectively). Both 
methods of SLN detection achieved 100% accuracy. Positive 
SLNs were identified in 14 (25.45%) and positive non-SLNs 
were confirmed in five (9.09%) patients, while 40 (72.73%) 
participants were both SLN and non-SLN negative. Skip 
metastases, defined as positive non-SLN with negative SLN, 
were diagnosed in only one woman (1.82%).
Based on lymph node involvement, the following four 
groups of patients were distinguished and included in further 
analysis: Group A (n = 40), SLN negative and non-SLN 
negative; Group B (n = 9), SLN positive and non-SLN negative; 
Group C (n = 5), SLN positive and non-SLN-positive; and 
Group D (n = 1), SLN negative and non-SLN positive (skip 
metastases). Group D was excluded from further evaluation 
due to the limited number of cases.
LVD in tumours and at the peri-tumour border. Intra and 
peri-tumour LVD was determined (Fig. 2). Both intra- and 
peri-tumour LVD were independent of patient age (p = 0.672 
and 0.416, respectively), tumour grade (p = 0.881 and 0.779, 
respectively), disease stage (p = 0.956 and 0.798, respectively), 
and lymphatic spread (p = 0.649 and 0.712, respectively). 
Additionally, there were no differences in median intra-
tumour or per-tumour LVD among Groups A, B, and C 
(p = 0.273) (Tab. 2). However, peri-tumour median LVD was 
significantly higher compared with intra-tumour expression 
in Groups A, B, and C (p < 0.001) (Tab. 2), as well as in the 
Figure 1. Flow diagram demonstrating participant recruitment procedure.
*Group D was excluded from analyses due to the limited number of cases
125
Annals of Agricultural and Environmental Medicine 2020; Vol 27, No 1
Magda Piechowicz, Marcin Mikos, Tomasz Banas, Krzysztof Okon, Milosz Pietrus, Marta Balajewicz-Nowak et al. Metastatic and non-metastatic sentinel inguinofemoral…
entire patient cohort (1.753 IQR: 1.571 vs. 0.537 IQR:0.621); 
p < 0.001).
LVD in sentinel and non-sentinel inguinal lymph nodes. 
LVD was confirmed in SLN and non-SLN (Fig. 2) and was 
independent from left/right localization (p = 0.254 and 0.259, 
respectively), patient age (p = 0.267 and 0.501, respectively), 
and tumour grade (p = 0.143 and 0.266, respectively) in 
both groups; whereas, disease stage (p < 0.001 and p = 0.003, 
respectively) and lymphatic spread (both p < 0.001), were 
associated with LVD.
Median LVD in SLN was significantly lower in patients 
from Group A (negative SLN) than those in Groups B 
(p < 0.001) and C (p = 0.005) (both positive SLN), while no 
significant differences in median LVD in SLN were observed 
between Groups B and C (Tab. 2). In non-SLN, the highest 
median LVD observed was in Group C (positive non-SLN), 
compared with Groups A (p = 0.001) and B (p = 0.027) (both 
negative none-SLN), with no differences in median LVD 
expression observed between Groups A and B (Tab. 2).
Further detailed analysis revealed that in Group A (patients 
free from any nodular involvement), median LVD expression 
was higher in SLN, compared with matched non-SLN 
(p = 0.012) (Tab. 2). In Group B, metastatic SLN exhibited 
significantly higher median LVD compared with matched 
involvement-free non-SLN (p = 0.015) (Tab. 2). No differences 
in median LVD expression between SLN and matched non-
SLN (both positive for metastases) were observed in Group 
C (Tab. 2).
DISCUSSION
The results of this study confirm the feasibility and clinical 
utility of SLN detection procedures in squamous vulvar 
cancer. The obtained findings are consistent with those of De 
Cicco et al. and Sliutz et al., who reported a 100% detection rate 
Table 1. Clinical and pathological characteristics of patients with primary 
squamous vulvar cancer
Total cohort (n=55)
Median age at therapy [years] (IQR*); 
min.-max.
72 (7.50)
64.00 – 87.00
FIGO** stage
IA
IB
II
IIIA
IIIB
IIIc
IV
0 (0.00%)
40 (72.73%)
0 (0.00%)
10 (18.18%)
4 (7.27%)
1 (1.82%
0 (0.00%)
Grade
1
2
3
31 (56.36%)
21 (38.19%)
3 (5.45%)
Adjuvant treatment
None
Radiotherapy (RTH)
Chemotherapy (CHT)
40 (72.73%)
15 (27.27%)
0 (0.00%)
History of CIN #
Positive
Negative
12 (21.82%)
43 (78.18%)
History of tobacco use
Yes
No
36 (65.45%);
19 (34.55%)
History of vulvar lichen planus
Yes
No
1 (1.82%)
54 (98.18)
History of vulvar lichen sclerosus
Yes
No
2 (3.64%)
53 (96.36%)
Median number of SLN##
(IQR*); min.-max.
1 (1)
Median number of non-SLN###
(IQR*)
4 (1)
*IQR – interquartile range; **International Federation of Gynecology and Obstetrics classification 
of vulvar cancer; #CIN – cervical intraepithelial neoplasia; ##SLN – sentinel inguinofemoral lymph 
nodes; ###non-SLN – non-sentinel inguinofemoral lymph nodes.
Figure 2. Lymphatic vessels in metastatic lymph nodes (1-A), non-metastatic lymph nodes (1-B), tumour specimen (1-C), tumour-stroma border (1-D), identified 
by immunochemistry staining using the D2–40 monoclonal mouse antibody (magnification X400)
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using Technetium-99-m-labeled nanocolloid, with or without 
blue dye [11, 12]. Additionally a meta-analysis performed 
by Brincat et al. confirmed the safety and feasibility of SLN 
biopsy in vulvar cancer [13].
There is increasing evidence to support the promotion 
of metastasis by primary tumours through induction of 
the formation of a supportive microenvironment in a 
secondary organ site, termed the pre-metastatic niche [14]. 
Niche formation occurs as an ordered temporal sequence 
of events, one of which is lymphangiogenesis. There is 
experimental data demonstrating that primary tumours 
induce the growth of new lymphatic vessels within draining 
lymph nodes before they metastasize [15]. The expansion 
of the lymphatic network in draining lymph nodes has 
been referred to as the ‘lymphvascular niche’ [7]. It is likely 
that the endothelium of newly-formed lymphatic vessels 
promotes the lymphatic spread of tumours; however, the 
roles of lymphatic vessels within the pre-metastatic niche in 
the metastasis of human cancer are poorly understood and 
rarely investigated. Modification of the microenvironment to 
facilitate development of a secondary tumour in lymph nodes 
initiated by a primary tumour before, and independently 
of, the physical presence of metastatic cancer cells, has 
been observed in human cancers, including breast and 
tongue carcinomas [9]. The current study examined the 
process of lymphangiogenesis in squamous cell primary 
vulvar cancer by measuring lymphvascular density within 
tumours, peri-tumourally, and in sentinel and non-sentinel 
inguinal lymph nodes. Although LVD is not universally 
recognized as a measure of lymphangiogenesis, there is 
agreement that the lymphatic system initially present within 
and around a tumour generally responds to lymphangiogenic 
growth factors by proliferation and/or sprouting, and the 
density of lymphatic microvessels is significantly increased 
during tumour development, which indirectly indicates 
lymphangiogenesis supporting metastasis [16].
Lymph vascular density was higher in peritumour stroma 
than within tumours of the vulva, and both within- and 
peritumour LVD was independent of tumour stage. The 
difference in density of lymph vessels between the tumour 
and peritumour stroma is typical of both human tumours 
and animal models [17]. Although the intratumour lymphatic 
system provides an interface for lymphatic vessel invasion 
and metastasis, they are not considered crucial for increasing 
lymph node metastasis [18]. In some human cancers, 
intratumour lymphangiogenesis correlates with lymph node 
metastases, while in others there is no such correlation [19, 20, 
21]. The results of an investigation of vulvar cancer reported 
by Goes et al. suggest that increased intratumour LVD is 
associated with a lower rate of lymph node metastasis and 
favorable prognosis in vulvar squamous carcinomas [22]. 
Compared with tumour lymphangiogenesis, lymph node 
lymphangiogenesis is poorly investigated in human cancer, 
hence its role remains largely unexplored.
The most interesting finding of the current study is 
the demonstration for the first time of differences in 
lymphvascular density in inguinofemoral lymph nodes 
in squamous vulvar cancer. In cases with no lymph node 
metastases, the density of lymphatic vessels in the sentinel 
lymph nodes was higher than that in non-sentinel nodes. 
Median LVD was significantly lower in negative SLN, 
compared with both positive SLN and negative non-SLN. 
The data obtained in the current study confirm that the only 
independent factor significantly correlated with high LVD in 
SLN was the presence of metastases, whereas tumour stage, 
tumour grade, and patient age were not associated. Similar 
changes in lymph nodes were detected in animal models of 
cancer lymphangiogenesis [23]. The findings of Ishii et al. 
suggest that, in oral squamous cell carcinoma, the primary 
tumour actively induces lymphangiogenesis in SLNs prior to 
the onset of metastases, and that tumour-derived VEGF-C 
is important in this process [24]. Lymphangiogenesis in the 
regional lymph nodes is an independent prognostic marker 
in rectal cancer patients after neoadjuvant chemotherapy, 
as determined by Jacob et al. [25]. Increased SLN metastasis 
and  lymphangiogenesis is associated with metastatic 
involvement of non-sentinel axillary lymph nodes in breast 
cancer [26].
The observations of squamous vulvar cancer in the 
current study appear to support the hypothesis that 
lymphangiogenesis and lymphatic remodeling are associated 
with the spread of lymphatic cancer. According to this 
hypothesis, primary tumours might prepare subsequent sites 
for metastasis. Hence, alterations in the lymphatic system of 
the tumour would facilitate the migration of tumour cells 
into sentinel lymph nodes [27]. New lymphatic vessels in 
tumour-draining lymph nodes could represent a metastatic 
niche for cancer cells, which facilitate further metastatic 
transformation of tumour cells, and potentially increase 
the spread of tumour cells to distant sites in the body [28]. 
Moreover, SLN lymphangiogenesis can contribute to the 
inhibition of anti-tumour-specific immune responses [29].
The large disproportion in the number of patients between 
the study groups may be considered a potential limitation of 
the study. Although the authors acknowledge that the results 
must be interpreted with caution; however, vulvar cancer is 
a rare gynaecological malignancy. Additionally, suspicion of 
lymph node involvement is a core contraindication for SLN 
procedure; therefore, in every patient lymph node metastases 
were mandatory excluded, based on clinical examination and 
imaging tests. This is the reason for the large disproportion 
between study groups, this is the result of the proper selection 
patients not influencing a collection bias. The strength of this 
study was its comprehensive analysis of LVD in SLN and non-
SLN; additionally, every cases of vulvar cancer was confirmed 
in histopathological reevaluation of specimens that were 
independently assessed by two experienced pathologists to 
confirm their diagnoses and classifications.
Further studies are required to ascertain tumour-induced 
changes in regional and distant lymphatic systems, and their 
roles in cancer development and progression in the context 
of rapidly expanding targeted therapy approaches.
CONCLUSIONS
The data obtained allow the authors to make the following 
conclusions:
1) SLN detection by an experienced surgeon is a safe and 
feasible procedure in vulvar cancer, that can facilitate 
reduction of the adverse effects associated with 
inguinofemoral lymphadenectomy in selected cases.
2) A significantly higher median peri-tumour LVD was 
observed, compared with intra-tumour LVD, irrespective 
of tumour grade or disease stage, which was not associated 
with SLN or non-SLN involvement.
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3) Both SLN and non-SLNs showed significantly elevated 
median LVD values if they contained metastases.
4) In patients without nodular involvement, SLN showed 
significantly higher median LVD, compared with non-
SLNs, which indicates SLN preparation for hosting 
metastases, and thus requires further investigation. 
Additionally, women with positive SLNs and non-SLNs did 
not show significant differences in median LVD between 
SLNs and non-SLNs.
5) Significantly higher median LVD expression in positive 
SLNs, compared with negative non-SLNs, was observed 
in women in Group B, which may be the result of SLNs 
involvement; however, the processes involved in preparing 
the lymph node for hosting metastases may also be 
important for generating LVD and cannot be ruled out.
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